Clinical Researcher: Pre-Competitive Research Propels Modernization of Drug Development Using Modeling and Simulation

It’s hard to imagine that 37 leading, global biopharmaceutical companies would be willing to partner to develop a new technology and progress a scientific field, but that is exactly what the members of the Simcyp Consortium have achieved. Working together in a pre-competitive, collaborative research environment, the consortium’s members are advancing physiologically based pharmacokinetic (PBPK) … Continued

Accelerating Therapeutics for COVID-19

This webinar will explain lessons learned from preparing for and responding to viral outbreaks such as H5N1 and pH1N1 influenza and discuss how insights from model-informed drug development approaches can spur access to medicines for patients.

Certara’s Simcyp MechDermA Model Achieves Regulatory Approval: Demonstrates Virtual Bioequivalence in Dermal Drug Development

Demonstrating bioequivalence (BE) remains the key regulatory hurdle for generic drug approval.  However, this is a challenging process for today’s complex drugs and alternative delivery methods.  Consequently, patients lack availability of thousands of generics. This problem is especially vexing for topical drugs and trans-dermal patches. Regulatory Support for Expediting the Development of Dermal Generics The … Continued

What’s New in the Simcyp Simulator v19?

This webinar explained how the latest updates in the Simcyp Simulator v19, Certara’s physiologically-based pharmacokinetic (PBPK) modeling and simulation platform, will support developing safer, more effective medications faster.

Back to top